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Abstract
Aspergillus is a mould that is ubiquitous in nature and may lead to a variety of infectious and allergic diseases depending on the 
host’s immune status or pulmonary structure. Invasive pulmonary aspergillosis occurs primarily in patients with severe immuno-
deficiency. The significance of this infection has dramatically increased with growing numbers of patients with impaired immune 
state associated with the management of malignancy, organ transplantation, autoimmune and inflammatory conditions; critically 
ill patients appear to be at an increased risk as well. The introduction of new noninvasive tests, combined with more effective 
and better-tolerated antifungal agents, has resulted in lower mortality rates associated with this infection. Chronic pulmonary 
aspergillosis is a locally invasive disease described in patients with chronic lung disease or mild immunodeficiency. Recently, the 
European Society for Clinical Microbiology and Infectious Diseases provided a more robust sub-classification of this entity that 
allows for a straightforward approach to diagnosis and management. Allergic bronchopulmonary aspergillosis, a hypersensitivity 
reaction to Aspergillus antigens, is generally seen in patients with atopy, asthma or cystic fibrosis. This review provides an update 
on the evolving epidemiology and risk factors of the major manifestations of Aspergillus lung disease and the clinical manifesta-
tions that should prompt the clinician to consider these conditions. It also details the role of noninvasive tests in the diagnosis of 
Aspergillus related lung diseases and advances in the management of these disorders. 
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Introduction
Aspergillosis refers to a variety of con-
ditions caused by aspergillus spp. — a ubiquito-
us saprophytic mold commonly found in soil, 
water, plants, and building materials [1]. First 
recognized in Florence in 1729, transmission 
is via inhalation of fungal spores, and mostly 
affects immunocompromised individuals or 
those immunocompetent individuals with un-
derlying chronic lung diseases [2]. A. fumi-
gatus  accounts for most human infections, 
followed by A. flavus, A. terreus, A. niger, and 
A. nidulans [3]. Aspergillosis can cause a spec-
trum of pulmonary disease depending the cha-
racteristics of the individual host: 1) invasive 
pulmonary aspergillosis; 2) chronic pulmonary 
aspergillosis; and 3) allergic bronchopulmonary 
aspergillosis. 
Invasive pulmonary aspergillosis
Invasive pulmonary aspergillosis (IPA) is 
the most severe on the spectrum of diseases 
caused by Aspergillus spp. It mostly affects the 
immunocompromised individuals, and carries 
a high mortality rate ranging from 38% to 75% 
with high economic burden [4–9]. Despite advan-
ces in medical therapy, incidences of IPA have 
increased remarkably, owing to more aggressive 
chemotherapy regimens for hematologic ma-
lignancies, increasing number of solid organ 
transplants, and expanding use of immunosup-
pressants [10]. In two large studies examining 
autopsy data between 1978 to 1992, and 1993 to 
2005, the incidence of aspergillus as the causa-
tive organism increased from 17% to 60% from 
1978 to 1992, and this remained stable between 
1993 to 2005. Despite changes in epidemiology, 
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aspergillus remained as the most common fungal 
pathogen [11, 12].
IPA is characterized by the invasion of 
pulmonary arterioles and lung parenchyma by 
Aspergillus hyphae that leads to ischemic ne-
crosis, intravascular thrombosis, hemorrhagic 
infarct from rapid hyphal growth [13, 14]. The 
angioinvasion of distant organs via hematogenous 
dissemination frequently involves the kidneys, 
liver, spleen, and the central nervous system.
Risk factors
At risk patient populations have classically 
included immunocompromised individuals such 
as recipients of allogeneic hematopoietic stem cell 
transplantation (HSCT), solid organ transplant 
(SOT) recipients, patient on prolonged cortico-
steroids, individuals with advanced AIDS and 
chronic granulomatous disease [15]. 
Inhalation of aspergillus spores are common, 
and in most immunocompetent hosts, mecha-
nisms are in place to prevent its germination 
and growth. Respiratory epithelial cells and 
mucociliary clearance act as first line of defense 
against inhaled aspergillus species [16]. Alveolar 
macrophages activation by NADPH oxidase acti-
vation contributes to both conidial clearance and 
secretion of inflammatory mediators, resulting 
in recruitment of neutrophils and activation of 
cellular immunity. Neutrophils play an important 
role, via NADPH oxidase dependent pathway 
in inducing hyphal damage; and via a NADPH 
oxidase independent pathway to inhibit conidial 
growth [16]. Highlighted in a study over 30 years 
ago, prolonged neutropenia has been a classic 
risk factor for IPA, with both the severity as well 
as the duration of neutropenia as contributing 
factors for risk of IPA [17]. It was estimated that 
patients with granulocytopenia developed signs 
of IPA at a rate of 1% per day in the early phase, 
and approximately 4.3% per day between days 
24–36 [17]. 
More recent years, IPA has been increasingly 
reported in non-neutropenic, immunocompe-
tent but critically ill patients such as those with 
severe influenza A and B [18, 19] liver disease 
or those with COPD exacerbation who received 
systemic and or inhaled corticosteroids [20]. 
One multicenter cohort study found influenza 
to be independently associated with IPA (95% CI 
2.63–10.26; p < 0.0001), and such patients had a 
~51% mortality rate [21]. Incidence rate of IPA 
is as high as 16% in patients with alcoholic liver 
cirrhosis [22]. The pathogenesis of IPA in these 
patients tends to be nonangioinvasive, and there 
is an exacerbated inflammatory environment 
resulting in tissue injury [14]. 
Clinical presentation
Early symptoms can be non-specific, inc-
luding dry cough and fever, and pleuritic or 
non-specific chest pain. Immunocompromised 
patients often do not have fever due to their 
inability to mount an adequate inflammatory re-
sponse. Progression to pneumonia occurs within 
1–2 days [13]. Angioinvasive IPA predominates 
in neutropenic patients, with rapid progression 
and clinical deterioration occurring over hours to 
days [23]. Hemoptysis is suggestive of pulmonary 
infarction, and sometimes massive hemoptysis 
is seen in patient with formation of cavitation 
during neutrophil recovery phase. 
Diagnosis
Diagnosing IPA is difficult in patients with 
known risk factors. Diagnosing IPA in those 
critically ill patient without classic risk factors 
can be even more challenging, as studies have 
found IPA to be frequently misdiagnosed based 
on autopsy [20, 24].
The gold standard for diagnosis is via biop-
sy of lung tissue, in combination with positive 
culture of Aspergillus spp. from the biopsy spe-
cimen. However, patients with suspected IPA 
often have profound thrombocytopenia, or are 
clinically unstable to undergo biopsy proce-
dures. Focus has been placed on noninvasive 
biochemical markers that allows for rapid and 
reliable diagnosis of IPA. 
Galactomannan (GM) is part of the cell wall 
of aspergillus that is released during fungal gro-
wth[13]. The use of serum and bronchoalveolar 
lavage (BAL) GM is recommended by the In-
fections Diseases Society of America (IDSA) as 
a diagnostic marker for IPA in both adult and 
pediatric patients with hematological mali-
gnancy or recipient of allogeneic HSCT, with 
a sensitivity of ~70% [15]. However, its use is 
population specific, and sensitivity decreases in 
nonneutropenic patients, CGD patients, and tho-
se with SOT to as low as 20%. Furthermore, obta-
ining serum GM is not recommended in patients 
receiving antifungal therapy or prophylaxis, but 
rather should be obtained from BAL specimen. 
A Cochrane meta-analysis by Leeflang et al. 
conducted in immunocompromised patients 
demonstrated serum GM to have sensitivity 
varying between 78% to 63% and specificity of 
85% to 93%, depending on the optical density 
index (ODI) used as cut off from 0.5 to 1.5 re-
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spectively [25]. Similar study on GM obtained 
from BAL fluid showed similar trend and varia-
bility in sensitivity and specificity based on ODI 
used, with a decrease in sensitivity from 88% 
(75–100%, 95% CI) to 78% (61–95%, 95% CI), 
and increase in specificity from 81% (71–91%, 
95% CI) to 93% (87–98%, 95% CI) when a ODI of 
0.5 and 1 was compared [26]. Further increasing 
ODI to 1.5 significantly decreased variability of 
specificity, and appeared as a strong indicator 
of IPA. This increase in false negative rate and 
decrease in false positive rate with increasing 
ODI value should be taken into account when 
using GM as a diagnostic marker. A more recent 
systemic review and meta-analysis by Haydour 
and colleagues demonstrated serum GM had 
moderate sensitivity of 71% (64–78%, 95% CI) 
and high specificity of 89% (84–92%, 95% CI) 
[27]. ODI of 1 was considered to provide optimal 
sensitivity [79%, (60–91%, 95% CI)] and speci-
ficity (88%, 78–94%, 95% CI) [28]. Increased 
diagnostic accuracy was again demonstrated in 
BAL GM with overall sensitivity and specificity 
of 84% (73–91%, 95% CI) and 88% (81–91%, 
95% CI) respectively [27]. 
Beta-D-glucan (BDG) is another cell wall 
polysaccharide found on the cell walls of most 
fungi. A meta-analysis by Hou et al. included 
1068 patients from 11 studies found the sensiti-
vity and specificity of the diagnostic accuracy of 
serum BDG to be 75% (64–84%, 95% CI) and 87% 
(81–92%, 95% CI) respectively as a screening tool 
for invasive fungal disease [29]. Furthermore, the 
pooled sensitivity and specificity for IPA was 73% 
(62–86%, 95% CI) and 81% (64–85%, 95% CI) 
respectively [29]. The various type of BDG assays 
available, with different cutoffs for BDG levels 
created potential for error. Combining serum 
GM with serum beta-D-glucan (BDG) or having 
two positive BDG test consecutively significantly 
increases specificity [30].
Aspergillus PCR is more sensitive than re-
spiratory cultures, with a sensitivity and speci-
ficity of 79.2% (71–85.5%, 95% CI) and 79.6% 
(69.9–86.6%, 95% CI) respectively [31]. When 
two positive PCR results are required, sensitivity 
and specificity were 59.6% (40.7–76.0%, 95% CI) 
and 95.1% (87.0–98.2%, 95% CI). The increased 
specificity in two consecutive tests indicate value 
of using PCR as a diagnostic screening tool. Avni 
et al. demonstrated higher summary sensitivity 
and specificity of BAL PCR of 90% (77–96%, 
95% CI) and 96% (93–98%, 95% CI) respectively 
[32]. When including only studies adhering to 
European Organization for Research and Treat-
ment of Cancer and the Mycoses Study Group 
(EORTC/MSG) diagnostic criteria, sensitivity and 
specificity decreased to 77% and 93%. Study also 
found reduced sensitivity of BAL PCR in patients 
receiving antifungal treatment or prophylaxis. 
The sensitivity of aspergillus PCR on BAL fluid 
was higher, though there are instances of lowe-
red specificity that may be attributed to the fact 
that aspergillus often colonized in the lungs [33]. 
Due to lack of standardization and validation, 
the Aspergillus PCR has not been cleared by the 
FDA for clinical use in the United States [15]. The 
mycological tests used for diagnosis are summa-
rized in Table 1.
Radiographic imaging is frequently used to 
aid in diagnosis of IPA. HRCT is the preferred 
method at the early stages to identify lesions of 
IPA, with features including nodules, consolida-
tive lesions, and wedge-shaped infarcts. Charac-
teristic feature of IPA, especially in neutropenic 
patients, is the ‘halo sign’, which is a central 
nodule that’s > 1 cm in diameter surrounded 
by a ground-glass opacity reflecting hemorrhage 
[34] (Figure 1). Halo sign is seen only during the 
early stages of angioinvasion, and thus can be 
easily missed if CT scan is not done during this 
window. The ‘air crescent sign’ seen in ~50% of 
cases usually two weeks after disease progression, 
after the patient’s immune system has recovered 
from the initial insult. It is a crescentic area of 
radiolucency within the nodular opacity [34]. 
This represents the retracted and infarcted lung, 
and its presence may be too late to be helpful in 
making the diagnosis. CT findings in tracheobron-
chitis typically show thickened tracheobronchial 
wall with presence of centrilobular micronodu-
les arranged in a ‘tree-in bud’ pattern [34]. With 
increasing incidence of IPA in non-neutropenic 
patients, various CT image findings exist, with 
no typical findings described yet [35].
Based on the advancement in diagnostic tests 
and imaging studies, the European Organization 
for the Research and Treatment of Cancer/Myco-
ses Study Group (EORTC/MSG) consensus group 
revised its standard definition for IPA in 2008 
summarized in Table 2 [36]. 
Most recently, ATS guidelines in 2019 stron-
gly recommended the use of serum GM in severely 
immunocompromised patients with unexplained 
lung infiltrates suspected of IPA [37]. BAL-GM 
testing is strongly recommended in those patients 
with negative serum-GM but have strong risk 
factors of IPA, or those with positive serum-GM 
but have confounding factors for false-positive 
results [37]. 
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Treatment
Early diagnosis and initiation of treatment 
for IPA greatly enhances chance of survival. 
However, as previously discussed, the clinical 
signs and symptoms can be non-specific and 
characteristic imaging findings are frequently ab-
sent and requires a high index of suspicion from 
physicians. Previously established definition for 
establishing diagnosis of proven or probably IPA 
by EORTC/MSG is time consuming, and clinicians 
should not delay therapy in at risk patients due 
to the rapid clinical progression and high mor-
tality rate. 
The Infectious Disease Society of America 
(IDSA) and the European Society for Clinical 
Microbiology and Infectious Diseases endorses 
prompt treatment of IPA with antifungal agents. 
The drug of choice remains voriconazole, which 
has improved survival when compared with am-
photericin B [38]. Typical treatment dose for IPA 
is 6 mg/kg IV every 12 hours on day 1, followed 
by 3 mg/kg every 12 hours. Transition to oral me-
dication is appropriate once the patient is stable. 
Voriconazole is metabolized in the liver, and is 
both a substrate and an inhibitor of CYP2C19 and 
CYP3A4, and as a result can cause significant 
drug-drug interactions and thus requiring tho-
rough medication review prior to initiation [15]. 
Major side effects include but are not limited to 
transient visual disturbances, dose-related hepa-
totoxicity, skin rash, reversible central and peri-
pheral neurologic symptoms, and cardiovascular 
events. Therapeutic drug monitoring (TDM) has 
been utilized more commonly for monitoring ef-
ficacy and safety of treatment of IPA as patients 
often have multiple comorbidities or underlying 
illnesses that affect the drug absorption, meta-
bolism, and clearance. Target serum trough level 
of > 1–1.5 µg/mL for most patients is considered 
adequate, and level should be checked 2–7 days 
after initiation of therapy, and further monitoring 
is based on patient’s clinical status, disease seve-
rity, and concern for toxicity [15, 39]. 
A more recent development is the use of 
isavuconazole as the alternative primary treatment 
of choice in hematological patients, which showed 
to be non-inferior to voriconazole in the SECURE 
trial, with better tolerance [38, 40]. Though less 
severe side effects, close attention should be 
Figure 1. Chest CT image showing right upper lobe nodule with halo sign 
in a patient with IPA
Table 1. Mycological tests for diagnosis of IPA
Sensitivity/specificity (95% CI) LR (95% CI)/ PPV/NPV ATS recommendations
Serum GM Sensitivity: 79% (60–91%) 
Specificity: 88% (78–94%) 
Positive LR: 6.6 (3.4–12.5)
Negative LR: 0.24 (0.11–0.50)
Strong recommendation for use in severe-
ly immunocompromised patient
BAL GM Sensitivity: 90% (77–96%)
Specificity: 94% (88–97%)
Positive LR: 14.3 (7.2–28.5)
Negative LR: 0.11 (0.04–0.26)
Strong recommendation for use in 
patients suspected of invasive fungal 
diseases
Serum BDG Sensitivity: 73% (62–86%) 
Specificity: 81% (64–85%)
Positive LR: 5.57 (3.89–6.23)
Negative LR: 0.34 (0.12–0.48)
Single blood/serum 
aspergillus PCR 
Sensitivity: 79.2% (71.0–85.5%)
Specificity: 79.6% (69.9–86.6%)
Positive LR: 3.8 (2.6–5.7)
Negative LR: 0.26 (0.18–0.36)
PPV: 42.8%
NPV: 95.1%
Strong recommendation for use in severe-
ly immunocompromised patients suspec-
ted of having IPA
2 blood/serum 
aspergillus PCR
Sensitivity: 59.6% (40.7–76%)
Specificity: 95.1% (87–98.2%)
Positive LR: 12.2 (4.2–35.3)
Negative LR: 0.42 (0.26–0.67)
PPV: 70.3%
NPV = 92.4%
BAL PCR Sensitivity: 77% (62–87.6%)
Specificity: 93.5% (90.6–95.6%)
PPV: 67.6%
NPV: 94.6%
Strong recommendation for use as a part 
of evaluation in severely immunocompro-
mised patients suspected of having IPA
FN — false negative; FP — false positive; LR — likelihood ratio; NPV — negative predictive value; PPV — positive predictive value
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paid to co-administration of medications that are 
CYP3A4 substrates and/or inducers [15]. 
Amphotericin B and its lipid derivatives are 
appropriate agents for initial and salvage therapy 
when use of voriconazole is contraindicated or 
not tolerated. In the case of liver insufficiency, 
liposomal amphotericin B is the generally the 
therapy of choice.
Echinocandins such as caspofungin, and mi-
cafungin work by the noncompetitive inhibition 
of the synthesis of BDG [15]. Monotherapy with 
echinocandin is not generally recommended as 
initial treatment of IPA, however, it is an effec-
tive salvage therapy when used as monotherapy 
or in combination with other antifungal agents 
[15, 41, 42]. Specifically, synergistic effects have 
been described in multiple studies when used in 
combination with triazoles [43, 44]. Their long 
half-life of > 10 hours allows for daily dosing, 
and are relatively well tolerated, with few side 
effects, and few drug interactions. Echinocandins 
are available in parenteral form only.
There is no clear consensus regarding dura-
tion of therapy with antifungals, with the IDSA 
recommending minimum of 6–12 weeks depen-
ding on clinical severity and disease course. 
Surgical resection is reserved for patient with 
IPA and massive hemoptysis, or for localized IPA 
that’s refractory to medical treatment [15]. 
Prophylaxis regimen for at risk populations 
during prolonged neutropenia is strongly recom-
mended by IDSA. Posaconazole and voriconazole 
demonstrated superiority versus other triazoles 
[15]. Other agents used for prophylaxis include 
micafungin, amphotericin B and caspofungin. 
Non-pharmacologic interventions (i.e. 
environmental strategies) such as the use of HEPA 
filters, with directed airflow in patient rooms, and 
positive pressure ventilation rooms for special at 
risk patients are utilized to prevent nosocomial 
pulmonary aspergillosis [45].
Chronic pulmonary aspergillosis
Chronic pulmonary aspergillosis (CPA) con-
sists of a spectrum of disease patterns with va-
rying degree of overlap in mostly immunocompe-
tent individuals with underlying lung diseases, 
especially those with prior history of tuberculosis 
or non-tuberculous mycobacteria (NTM) [46]. 
It is estimated that approximately 3 million 
people suffer from CPA globally, with roughly 
1.2 million develop CPA as a sequalae of pulmo-
nary TB [47, 48]. Other associated lung diseases 
include chronic obstructive pulmonary disease 
(COPD), emphysema, allergic bronchopulmonary 
aspergillosis (ABPA), asthma, cystic fibrosis, prior 
pneumothorax, prior treated lung cancer, sarco-
idosis, ankylosing spondylitis, pneumoconiosis, 
and pneumonia [46, 49]. 
The most common form of CPA is chro-
nic cavitary pulmonary aspergillosis (CCPA), 
which was previously named complex aspergil-
loma, in which one or more pulmonary cavities 
exist that can enlarge over time (Figure 2) [50]. 
When untreated, CCPA may progress to chro-
Figure 2. Chest CT image showing right upper lobe fungal ball in a patient 
with CPA
Table 2. Diagnostic criteria for invasive pulmonary aspergillosis
Diagnosis Criteria
Proven Sterile specimen obtained from a clinically or radiologically abnormal site with:
— histo- or cytopathological evidence or direct microscopic identification of hyphae invading the lung tissue or 
— positive culture result for aspergillus 
Probable ≥ 1 host factor and
≥ 1 clinical criteria and 
≥ 1 mycological evidence (positive Aspergillus microscopy or culture from the sputum or BAL or positive antigen assay 
of GM or BDG
Possible Host factor and 
clinical criteria consistent with the infection, no mycological evidence of aspergillus
BAL — Bronchoalveolar Lavage; BDG — b-D glucan; GM — galactomannan 
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nic fibrosing pulmonary aspergillosis (CFPA), 
with extensive pulmonary fibrosis in one or 
more lobes causing significant loss of lung 
function [50]. 
Aspergilloma and aspergillus nodule are less 
severe manifestations of CPA. Aspergilloma is a 
fungal ball in a pre-existing lung cavity and con-
sists of aspergillus hyphae, fibrin, mucus, debris, 
inflammatory cells, and other degenerating blood 
and epithelial elements [13]. The term simple 
pulmonary aspergilloma is used when a single 
aspergillus fungal ball occupies a pulmonary ca-
vity in a non-immunocompromised patient with 
no or minor symptoms, and have not progressed 
over at least 3 months [50]. The most common 
underlying cavitary pulmonary diseases involved 
is prior tuberculosis cavities. It is estimated that 
over 11–17% of reported aspergilloma are in 
patients with post-tuberculosis cavities. Other 
diseases include sarcoidosis, histoplasmosis, 
blastomycosis, AIDS, pneumonia, lung abscess, 
pulmonary fibrosis, asbestosis, rheumatoid no-
dules etc. [13]. 
An aspergillus nodule is defined as one or 
more nodules (< 3 cm) that usually have no 
cavitation within. These are usually found in-
cidentally on chest imaging. 
Subacute invasive aspergillosis (SAIA), for-
mally known as chronic necrotizing pulmonary 
aspergillosis, is comparably more rapidly progres-
sive and locally destructive disease, and can be 
seen in mild to moderately immunosuppressed 
patients [50]. Diagnosis and treatment of SAIA is 
similar to that of IPA, but with a slower course 
of progression. 
Clinical presentations
Most patients present with indolent, non-spe-
cific symptoms which cause delayed or missed 
diagnosis. Productive cough is the most common 
symptom. Other symptoms include shortness of 
breath, fatigue, weight loss, night sweats, fever 
and chest pain. Systemic symptoms are generally 
absent in patients with aspergilloma or aspergillus 
nodules. Hemoptysis is one of the typically 
presentations of CPA and occurs in 50–90% of 
patients with aspergilloma and can be life-thre-
atening. 
Diagnosis
The European Society for Clinical Micro-
biology and Infectious Diseases (ESCMID), the 
European Respiratory Society (ERS) and the 
European Confederation of Medical Mycology 
(ECMM) established diagnostic criteria for CPA 
in 2016 as the following: 1) one or more cavities 
with or without a fungal ball or nodules present 
on thoracic imaging for ≥ 3 months; 2) direct evi-
dence of Aspergillus infection or an immunologi-
cal response to Aspergillus spp.; and 3) exclusion 
of alternative diagnoses (Table 3). 
Similar criteria for CPA is published in the 
updated IDSA guideline in 2016 with the follo-
wing criteria: patient with no or minimum immu-
Table 3. Diagnostic criteria for different manifestation of chronic pulmonary aspergillosis 
Symptoms Imaging finding Confirmatory
Aspergilloma Minimal or asympto-
matic 
Fungal ball with no radio-
graphic progression  
over ≥ 3 months
Positive aspergillus IgG (~90% sensitive) or precipitins. 
If negative, other evidence of aspergillus infection is 
required
CCPA Significant respira tory 
and/or constitutional 
symptoms
One or more cavities ± 
aspergilloma with radio-
graphic progression  
over ≥ 3 months
Any of the following once other diagnosis are excluded:
Positive aspergillus IgG or precipitins
Positive aspergillus antigen/DNA in respiratory fluids
Percutaneous or excision biopsy showing fungal hyphae/
aspergillus spp. growing from a cavity
CFPA Significant loss of lung 
function
Fibrosis with destruction  
of ≥ 2 lung lobes
Serological or microbiological evidence of aspergillus 
spp.
Aspergillus nodule Asymptomatic ≥ 1 nodule
Usually < 3 cm, may or 
may not cavitate
Histological evidence of aspergillus
SAIA Significant respira tory 
and/or constitutional 
symptoms
Variable features including 
cavitation, nodules, pro-
gressive consolidation with 
radiographic progression  
in 1–3 months
Positive aspergillus IgG or precipitins or
Positive aspergillus antigen
Biopsy showing hyphae invasion of lung tissue
CCPA — chronic cavitary pulmonary aspergillosis; CFPA — chronic fibrosing pulmonary aspergillosis; SAIA — subacute invasive aspergillosis
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nocompromise; with varying degree of underlying 
pulmonary disease; who have at least 3 months 
of chronic pulmonary symptoms or chronic sys-
temic illness or progressive radiographic abnor-
malities including cavitation, pleural thickening, 
pericavitary infiltrates, with or without fungal 
ball; and microbiologic evidence of aspergillosis 
infection [15]. The key difference is the ESCMID/ 
/ERS/ECMM guideline does not endorse detection 
of Aspergillus spp. in sputum nor serum galac-
tomannan as diagnostic tests due to high rates 
of colonization and low sensitivity respectively. 
Though studies included patients with both CPA 
and IPA, the overall sensitive and specificity of 
utilizing BAL-GM aspergillus antigen assay (50 
to 100% sensitivity, 77 to 100% specificity) is 
superior to that of serum-GM (9 to 67.5% sen-
sitivity, 35 to 95% specificity) in diagnosing CPA 
[51–56]. Cut off level used also varied in these 
studies.
Based on clinical suspicion, plain chest ra-
diograph is usually the initial imaging modality, 
and documented progression provides valuable 
information. CPA in general has a predilection 
for the upper lobes of the lungs [34]. CT scan 
provides more detailed evaluation of the lung 
parenchyma than plain films [57]. Many features 
of radiographic findings show significant overlap 
between the spectrum of diseases.
Simple aspergilloma appears as a solid oval 
opacity within a lung cavity, typically in the 
upper lobe, with a surrounding ‘monod’ or ‘air 
crescent’ as the mass is typically separated from 
the cavity wall forming an air space [58, 59]. The 
mass appears to move with changes in position. 
The radiographic appearance stays stable for 
months, in contrast to CCPA. 
Hallmark of CCPA is consolidation, frequ-
ently in the upper lobes, that progress over time 
to cavitation and may lead to volume loss. Ca-
vities vary in size, and cavity wall may be thin 
or irregularly thickened, with adjacent pleural 
thickening. CT of the lung allows for earlier dia-
gnosis, showing thickening of the cavity wall and 
surrounding pleura. 
CFPA result from untreated CCPA, with 
extensive pulmonary fibrosis involving one or 
more lobes, but commonly involving the whole 
hemithorax [50].
Aspergillus nodules can appear similar to ma-
lignancy, NTM, actinomycosis, or rheumatoid no-
dules, and can be difficult to differentiate based on 
radiologic imaging alone. Most are round, though 
spiculate edges are seen [50]. SAIA usually appe-
ar as a single area of consolidation in the upper 
lobes that progress to thin-walled cavity within 
days or weeks. There may be associated pleural 
thickening, fungus balls, pneumothorax, and 
pleural effusion seen [50]. 
Treatment
Treatment for CCPA is aimed at symptom im-
provement, to prevent and/or reduce hemoptysis 
and progression of lung fibrosis. Oral azole the-
rapy with itraconazole (200 mg twice daily with 
therapeutic drug level monitoring) or voriconazo-
le (150–200 mg twice daily with therapeutic drug 
level monitoring) is well-established first-line 
therapy [15, 60, 61]. Some may favor use of vori-
conazole in patients with heavy fungal load due 
to higher reported resistance rate to itraconazole, 
however, there has been little clinical evidence 
supporting this approach [15, 50]. Few studies 
compare the efficacy of itraconazole verse vori-
conazole, and selection have largely been based 
on tolerability and cost. Tashiro et al. performed 
a retrospective analysis based on two randomized 
control trials comparing outcomes of using vori-
conazole or itraconazole as initial maintenance 
therapy. A total of 160 study patients were inc-
luded, and they found no statistical difference in 
mortality between CPA patient treated with the 
two drugs, and no difference in rate of treatment 
discontinuation due to side effects [60]. 
As previously discussed, isavuconazole is 
a newer triazole approved for treatment of IPA. 
One study showed less adverse drug reaction in 
patient receiving isavuconazole. However, the 
study is limited by number, and the overall rate 
of discontinuation of therapy in both group were 
comparable [62]. Posaconazole (400 mg twice 
daily liquid form, or 300 mg once daily tablet) 
is used as a third-line agent, with better tole-
rance in some cases, though efficacy studies are 
limited  [63]. Failure on azole therapy and those 
with pan-azole resistance warrant intravenous 
therapy instead, and in acutely ill patients, initial 
treatment with intravenous antifungal therapy is 
appropriate. Corticosteroids should be avoided 
when possible unless otherwise indicated for 
underlying disease [15]. 
Hemoptysis frequently complicates CPA, and 
can be fatal. Oral tranexamic acid provides good 
control of hemoptysis in some cases. In cases of 
significant or life-threatening hemoptysis, bron-
chial artery embolization is indicated [15, 50]. 
Surgery can be considered in CCPA with severe 
hemoptysis or failed therapy, and studies have 
reported higher post-surgical complication rates 
in patient with CCPA  [64–66]. 
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Management options of Aspergilloma is depen-
dent on clinical symptoms. For asymptomatic pa-
tients, close follow up with observation is indicated. 
Definitive treatment is surgical resection for patients 
with adequate pulmonary function [50]. However, 
surgery can have serious post-operative complica-
tions including hemorrhage, bronchopleural fistula 
and thus invasive methods are frequently contrain-
dicated in patients due to underlying disease and 
poor pulmonary function [67]. Careful pre-operative 
assessment of respiratory status is necessary, and 
five-year survival after surgical treatment have been 
reported to be between 91–100% [64–66, 68] with 
low recurrence [69]. 
There is also no clear consensus regarding 
duration of treatment for CPA. For CCPA, a period 
of 4–6 months for initial treatment are generally 
recommended while monitoring for clinical re-
sponse [15, 50]. Relapse occur in over one third 
of treated cases [70], so more patients are left 
on long-term treatment, though the decision is 
individual based [50]. Common side effects were 
previously mentioned and often limit treatment, 
and drug resistance may develop. 
Much like treatment duration, clinical tools 
to assess clinical response to treatment is also 
debated. Radiographic monitoring with low-dose 
CT without contrast or chest radiographs are often 
used. Decrease in cavity and pleural thickness 
and the loss of fungal ball on imaging paralleled 
clinical response the most [71]. 
The five year mortality rate for CCPA is be-
tween 40–60% — with variability in geographic 
location [60, 72]. Significant poor prognostic 
factors include previous infection with NTM, 
COPD, pleural involvement, bilateral cavitary 
disease, presence of aspergillomas, low BMI, hy-
poalbuminemia, old age, and breathlessness [72]. 
SAIA is considered as CPA, but treated simi-
larly to acute invasive aspergillosis (IPA) due to 
its rapid progressive nature [50]. 
Allergic bronchopulmonary aspergillosis 
Allergic bronchopulmonary aspergillosis 
(ABPA) is an inflammatory pulmonary disease 
characterized by hypersensitivity reaction to 
colonization of airway by aspergillus fumigatus 
in susceptible individuals, most of whom are 
patients with asthma and cystic fibrosis (CF) 
[73–75]. The term allergic bronchopulmonary 
mycosis is used to describe the immune sensiti-
vity reactions to other fungal classes, though the 
predominant causative organism is Aspergillus 
fumigatus. ABPA was first described in literature 
in 1952 by Hinson et al., with most reported ca-
ses related to aspergillosis [76]. True prevalence 
is unclear due to variability in diagnosis, it is 
estimated that ABPA complicated up to 1–2% 
of asthma patients [77], and up to 15% of CF 
patients [78].
In susceptible individuals, Aspergillus fumi-
gatus colonizes the airway, germinates, and de-
velops mucus plugs that consist of hyphae and 
cause chronic allergic, inflammatory response that 
can ultimately lead to tissue and airway damage, 
bronchiectasis, and/or pulmonary fibrosis [79, 80]. 
The aspergillus spores release proteases 
and other antigens that trigger an immunologic 
response which involves an IgE-mediated type I 
hypersensitivity, an IgG-mediated type III hyper-
sensitivity reaction, as well as that of Th2 CD4 T 
cell-mediated immune response by activation of 
cascade of inflammatory cytokines [81]. 
Multiple host genetic predisposition have 
been identified, including mutations in CF trans-
membrane conductance regulator (CFTR), HLA
-DR 2 and 5 polymorphisms, IL-10 promoter 
polymorphisms and surfactant protein A poly-
morphism has been shown to be associated with 
increased susceptibility to ABPA, while HLA-DQ2 
polymorphism have been shown to protect aga-
inst ABPA  [82–87].
Clinical manifestations
ABPA typically presents in patient with dif-
ficult to control asthma, however, the spectrum 
of disease presentation can be variable. Clini-
cally, patients complain of symptoms including 
dyspnea, wheezing, thick, mucus-like productive 
cough, low-grade fever, malaise, and in some ca-
ses, hemoptysis [79, 88]. Clubbing can be seen in 
those with chronic bronchiectasis [89]. CF patient 
often present with worsening pulmonary function 
or new infiltrate on chest radiograph [90]. 
Plain chest radiographs may demonstrate 
either transient or permanent features consistent 
with ABPA including pulmonary opacities, “tram-
line shadows” indicating bronchial wall thick-
ening, ‘finger-in-glove’ and ‘toothpaste’ shadows 
from mucoid impaction causing dilated bronchi 
[75]. HRCT allows better assessment of the struc-
tural pattern of ABPA and is often the imaging of 
choice. Central bronchiectasis with peripheral 
tapering has been referred to as a distinct feature 
of ABPA, though bronchiectasis is not present in 
all cases, and in some, peripheral bronchiectasis 
have been observed [75, 91]. Bronchiectasis on 
CT is characterized as ‘signet ring’ and ‘string of 
pearls’ [73]. Other findings on HRCT include mu-
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coid impaction, mosaic attenuation, centrilobular 
nodules and ‘tree-in-bud’ opacities. High-attenu-
ation mucus (HAM) is when the mucus appears 
visually denser than the paraspinal skeletal mus-
cle, which is a pathognomonic finding of ABPA 
[75, 89, 92]. 
Diagnosis 
ABPA is likely underdiagnosed due to the 
variations in diagnostic criteria used globally [74]. 
Diagnostic criteria for ABPA was first proposed by 
Rosenberg et al. in 1977 [93–96]. Due to lack of con-
sensus and lack of definitive diagnostic test, many 
other criteria have been proposed [94–96]. The 
ABPA working group of the International Society 
for Human and Animal Mycology (ISHAM) pro-
posed an updated diagnostic and staging criteria 
in 2013 which included predisposing conditions 
of bronchial asthma or cystic fibrosis. Diagnostic 
features were divided into ‘obligatory’ and ‘others’. 
Obligatory criteria included either positive type I 
Aspergillus skin test or elevated A. fumigatus spe-
cific IgE levels AND elevated total IgE levels of 
>1000 IU/mL. At least two of the following other 
criteria are required: 1) presence of precipitating 
or serum IgG antibodies against A. fumigatus; or 2) 
radiographic pulmonary opacities consistent with 
ABPA; or 3) total eosinophil count of > 500 cells/mL 
in steroid naïve patients [89]. A. fumigatus specific 
IgE levels is the best screening test for ABPA and 
is more sensitive than Aspergillus skin test. On 
the other hand, total serum IgE level is a sensitive 
indicator of response to therapy and relapse [89]. 
Those with uncontrolled asthma and positive 
aspergillus specific IgE levels but total IgE level of 
less that cut off of 1000 IU/mL and do not meet all 
criteria are classified as severe asthma associated 
with fungal sensitization (SAFS). 
Bronchoscopy may reveal mucus plugs con-
taining aggregates of eosinophils, fungal hyphae 
that is also pathognomonic for ABPA [88]. ABPA 
was previously categorized into five stages: 1) acu-
te; 2) remission; 3) exacerbation; 4) corticosteroid 
dependent asthma; and 5) fibrotic lung disease 
[97]. The ISHAM working group added a stage 
zero for asymptomatic patients diagnosed with 
ABPA to allow for early recognition and potential 
treatment of such group [89]. 
Diagnosis of ABPA in CF patients poses ad-
ditional challenges as many features of clinical 
presentation overlaps including radiographic 
lung infiltrates, increased cough and sputum 
productions, and mucus plugs, thus the diagnosis 
is often delayed which in turn has detrimental 
effects as early treatment can prevent and slow 
down irreversible lung damages. Due to these 
challenges, CF Foundation consensus conferen-
ce in 2003 outlined guidelines specific for CF 
patients, with major difference being a lowered 
total serum IgE of 500 IU/mL used as part of the 
minimum criteria, and a high index of suspicion 
is needed in this patient population  [78]. 
Treatment
Goal of ABPA treatment aims at control of 
symptoms, prevention of exacerbations, and re-
duction in progression of disease complications 
such as end-stage lung fibrosis or cavitary dise-
ases. Treatment of asymptomatic ABPA patients 
is not clearly indicated, but close follow-up is 
recommended. Doubling of serum total IgE is an 
indicator for ABPA exacerbation. Oral glucocorti-
coids and antifungals have been used in the ma-
nagement of ABPAs, though decisions are based 
on patient response, disease severity, frequency 
of exacerbations, drug adverse effects, and any 
emerging antifungal resistance [15]. 
Systemic glucocorticoids are the main tre-
atment in the management of acute ABPA with 
its anti-inflammatory and immunosuppressive 
effects [89]. The optimal dosing is not well- 
-established. A common regimen starts with pred-
nisone 0.5 mg/kg daily for 14 days followed by 
0.5 mg/kg every other day with further tapering 
and discontinuation in 3 months [94]. There is 
a lack of clinical trials on the effectiveness of 
oral corticosteroids, but few case series have 
demonstrated responsiveness to prednisone with 
decline of total IgE, reduction in blood eosinophil 
counts, and clearance of radiographic lesions [91, 
98]. One unblinded randomized trial showed that 
medium dose of oral glucocorticoids is just as 
effective as high-dose oral glucocorticoids in the 
treatment of acute ABPA with fewer side effects 
[98, 99]. Clinical response to treatment is moni-
tored every 1–2 months with marked decrease in 
total serum IgE levels of > 35%, and resolution or 
improvement in radiographic infiltrates [75, 100]. 
Despite their effectiveness, rates of relapse during 
tapering have been reported as high as 50%, with 
some becoming steroid-dependent [91]. Chronic 
steroid use also puts patients at risk for adverse 
effects such as diabetes mellitus, hypertension, 
osteoporosis, and growth retardation.
Antifungal therapy including itraconazole 
and voriconazole have been used in the treatment 
of ABPA in select patients. They work by reducing 
the fungal burden thereby reducing the immu-
ne response. IDSA guideline recommend using 
both oral glucocorticoids and antifungals at the 
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initiation of treatment, while the ABPA working 
group of ISHAM reserves use of antifungals for 
patients who is intolerant of corticosteroid taper, 
or those with recurrent exacerbations [15, 89]. 
As the initial treatment option for acute ABPA 
however, a randomized, unblinded trial found 
prednisolone to be more effective than itraco-
nazole in achieving response (100% vs 88%; 
P = 0.007) , though itraconazole group had lower 
incidence of adverse reactions, and total decline 
in serum IgE, the time to first ABPA exacerbation 
and the number of ABPA exacerbations at follow
-up were similar between the two groups [101]. 
When used in glucocorticoid-dependent ABPA, 
addition of itraconazole at 200mg twice daily 
showed positive responses including reduction 
in glucocorticoid dose, decrease in serum IgE 
levels, and improvement in either pulmonary 
function or exercise tolerance, or improvement in 
pulmonary infiltrates [102]. Duration of therapy 
of 16 weeks have been suggested based on past 
trials to avoid drug adverse effects [102, 103]. 
Cases of Cushing’s syndrome have been reported 
in patient using both glucocorticoids and itraco-
nazole, especially those treated with inhaled cor-
ticosteroids, likely owing to itraconazole’s ability 
to impair glucocorticoid metabolism and thereby 
increasing plasma levels [104, 105]. Newer anti-
fungals include voriconazole, and posaconazole 
have shown promising clinical response, though 
more studies are needed to evaluate their use as 
currently only case series are available [106–108]. 
Lastly, nebulized amphotericin B was shown to 
reduce exacerbations in a case study involving 
21 patients with ABPA complicating asthma [109].
Omalizumab, a human monoclonal antibo-
dy against IgE have been shown in case studies 
to be an effective adjunct therapy in asthmatic 
patients with refractory ABPA despite first-line 
treatments. A systemic review including 102 pa-
tients with ABPA most of whom had experienced 
treatment failure with systemic glucocorticoids 
or anti-fungal treatment showed addition of oma-
lizumab decreased serum IgE level, decreased 
ABPA exacerbation (2.74 ± 2.31 [1–12] to 0.38 
± 0.7 [0–3], p < 0.001), and a steroid-sparing 
effect where 94% of patients either stopped or 
reduced prednisone dose [110]. No significant 
improvement in lung function was noted in this 
review [110]. Data supporting use of omalizumab 
use in ABPA patients with CF have been con-
tradictory, and overall, more clinical trials are 
needed to provide definitive support for use of 
omalizumab in ABPA patients. 
Conclusion
Pulmonary aspergillosis exists as a spectrum of 
pulmonary diseases from hypersensitivity reaction, 
to a slowly progressing destructive process, to acu-
te invasive disease with high mortality rate. Early 
diagnosis and treatment are imperative to prognosis. 
High index of suspicion, knowledge of risk factors, 
and rapid diagnostic approach that includes the 
utilization of non-invasive tests are steps that help 
in early diagnosis. Recent advances in antifungal 
therapy has significantly improved outcome of these 
diseases. Further studies are still needed for more ro-
bust diagnostic tools and better tolerated therapies. 
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